Literature DB >> 23021090

Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.

Hannes Steiner1, Nicolai Leonhartsberger, Brigitte Stoehr, Reinhard Peschel, Renate Pichler.   

Abstract

BACKGROUND: Retroperitoneal lymph node dissection (RPLND) is indicated after chemotherapy in case of radiologic incomplete remission or teratomatous elements in orchiectomy specimens. Open RPLND is associated with considerable morbidity, but technical difficulty of postchemotherapy laparoscopic RPLND (L-RPLND) can be significant; therefore, literature concerning pc L-RPLND is sparse.
OBJECTIVE: To evaluate feasibility and long-term oncologic outcome of postchemotherapy L-RPLND for clinical stage II disease at a single institution. DESIGN, SETTING, AND PARTICIPANTS: Records of patients with nonseminomatous germ cell tumor who underwent postchemotherapy L-RPLND between 1993 and 2010 were retrospectively reviewed. Unilateral template resection was used until a bilateral nerve-sparing approach was introduced in 2004. Follow-up investigations were performed at 3-mo intervals for the first 3 yr, every 6 mo for the next 2 yr, and annually thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: This was a descriptive analysis. RESULTS AND LIMITATIONS: The study cohort comprised 100 patients with stage II retroperitoneal disease (stage IIC: n=16; IIB: n=68; IIA with persisting tumor marker: n=16). Mean diameter of retroperitoneal masses before and after chemotherapy was 3.5 cm and 1.4 cm, respectively. Unilateral and bilateral templates were resected in 71 and 29 patients, respectively. Surgery was successfully completed in all but one patient, whose procedure was converted to open surgery due to bleeding. Mean operation time for unilateral and bilateral resection was 241 and 343 min, respectively. Mean blood loss was 84 ml. Postoperative complications were a large lymphocele in one patient and chylous ascites in another. Mean postoperative hospital stay was 3.9 d. L-RPLND specimens showed teratoma in 38 patients and active tumor in 2 patients. During a mean follow-up of 74 mo, one patient recurred. No recurrence was observed inside the applied surgical field. No patient died of tumor progression. After bilateral nerve-sparing postchemotherapy L-RPLND, 95.2% of patients reported antegrade ejaculation.
CONCLUSIONS: Postchemotherapy L-RPLND performed by experienced hands is feasible and associated with low morbidity and high oncologic efficacy.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23021090     DOI: 10.1016/j.eururo.2012.09.036

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  14 in total

1.  Post chemotherapy retroperitoneal lymph node dissection in germ cell tumor: robotic way.

Authors:  Girdhar S Bora; Pankaj Panwar; Ravimohan S Mavuduru; Sudheer K Devana; Shrawan K Singh; Arup K Mandal
Journal:  J Robot Surg       Date:  2016-08-08

2.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

Review 3.  Surgical strategies for postchemotherapy testis cancer.

Authors:  Saum Ghodoussipour; Siamak Daneshmand
Journal:  Transl Androl Urol       Date:  2020-01

Review 4.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

5.  [Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors. Laparoscopic management - limits and chances].

Authors:  S Aufderklamm; T Todenhöfer; J Hennenlotter; J Mischinger; A Sim; J Böttge; S Rausch; S Bier; O Halalsheh; A Stenzl; G Gakis; C Schwentner
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

Review 6.  Surgical removal of retroperitoneal tumors after chemotherapy treated testicular tumors.

Authors:  Allen Sim; Stefan Aufderklamm; Omar Halalsheh; Tilman Todenhöfer; Christian Schwentner
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

7.  Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.

Authors:  Terukazu Nakamura; Akihiro Kawauchi; Masakatsu Oishi; Takashi Ueda; Takumi Shiraishi; Hiroyuki Nakanishi; Kazumi Kamoi; Yoshio Naya; Fumiya Hongo; Koji Okihara; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2015-12-23       Impact factor: 3.402

8.  Robot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy.

Authors:  Sang Hyub Lee; Dong Soo Kim; Sung-Goo Chang; Seung Hyun Jeon
Journal:  Korean J Urol       Date:  2015-07-01

9.  Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.

Authors:  J L H Ruud Bosch; Joost M Blok; Henk G van der Poel; J Martijn Kerst; Axel Bex; Oscar R Brouwer; Simon Horenblas; Richard P Meijer
Journal:  World J Urol       Date:  2020-09-21       Impact factor: 4.226

10.  Robot-assisted retroperitoneal lymph node dissection: Feasibility and outcome in postchemotherapy residual mass in testicular cancer.

Authors:  Amitabh Singh; Smaranjit Chatterjee; Prashant Bansal; Abhishek Bansal; Sudhir Rawal
Journal:  Indian J Urol       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.